Navigation Links
1-year results of ADAPT-DES trial published in The Lancet
Date:7/26/2013

NEW YORK, NY -- Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less likely to develop bleeding complications. One-year results of the ADAPT-DES trial will be published online July 26, 2013, in The Lancet. The findings were first presented at last year's Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium.

ADAPT-DES is the largest study ever to explore the overall treatment implications of platelet reactivity on patient outcomes after successful coronary drug-eluting stent implantation. Researchers investigated the relationship between platelet reactivity during dual therapy with aspirin and clopidogrel and clinical outcomes such as stent thrombosis, major bleeding, and other adverse events.

The study enrolled 8,583 patients at 11 sites in the US and Germany who underwent a percutaneous coronary intervention (PCI) with at least one drug-eluting stent between January 7, 2008, and September 16, 2010. Researchers assessed platelet reactivity with the VerifyNow Aspirin, P2Y12, and IIb/IIIa tests. Patients were followed for one year to determine the relationship between platelet reactivity and subsequent events. At one year, stent thrombosis had occurred in 70 patients (0.8 percent), heart attack in 269 (3.1 percent), major bleeding in 531 (6.2 percent), and death in 161 (1.9 percent).

Platelet reactivity units (PRU), an index of platelet inhibition to clopidogrel, were measured by the VerifyNow P2Y12 test. High platelet reactivity, defined as a PRU of greater than 208, was present in 42.7 percent of patients. At one year, researchers found that high platelet reactivity was significantly associated with stent thrombosis (1.3 percent vs. 0.5 percent) and heart attack (3.9 percent vs. 2.7 percent), but was also found to be protective against major bleeding (5.6 percent vs. 6.7 percent). High platelet reactivity was also associated with one-year mortality (2.4 percent vs. 1.5 percent). However, because high platelet reactivity is also associated with other patient risk factors and baseline characteristics, multivariable modeling was also performed; it showed no independent association between high platelet reactivity and mortality.

"Results from the ADAPT-DES registry definitely demonstrate that high platelet reactivity after implantation of drug-eluting stents is an independent predictor of one-year stent thrombosis and heart attack, but it is also protective against major bleeding, both of which impact mortality," said lead investigator Gregg W. Stone, MD. Dr Stone is professor of medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Stone is also co-director of the Medical Research and Education Division at the Cardiovascular Research Foundation (CRF).

"Because of the counteracting effects of ischemia and bleeding, platelet reactivity was not an independent predictor of one-year mortality. Therefore, overcoming high platelet reactivity with more potent antiplatelet agents is unlikely to improve survival unless the beneficial effect of reducing stent thrombosis and heart attack can be separated from the likely increase in bleeding that results from greater platelet inhibition," said Dr. Stone.

Dr. Stone added: "Platelet reactivity on aspirin was unrelated to stent thrombosis, heart attack, or death, but may be related to bleeding. This raises questions as to the utility of aspirin in patients treated with drug-eluting stents."


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of landmark 11-year study on weight losss effect on heart disease risks published today
2. SchizLife.com Celebrates 1-Year Anniversary, Debunks Harmful Schizophrenia Myths
3. 1-year results of ADAPT-DES presented at TCT 2012
4. SEARCH study shows 1-year drop in HIV virus levels in rural Ugandan parish after campaign
5. Presentation of 1-year IVAN and 2-year CATT study results
6. Carb Back-Loading Diet Review: Results and Sample Meal Plan Exposed by Daily Gossip Magazine
7. New Results from Orriant’s Corporate Wellness Programs are Demonstrating the Benefits of Tobacco Cessation
8. Beverly Hills Hair Restoration Surgeon Revises Unnatural Hair Transplant Results, Releases High-Definition Video of FUE Procedure
9. Weill Cornell presents updated results from Phase 3 trial of IVIG for Alzheimers disease
10. Monroe, CT Dental Implants Are Now Computer Guided from Dr. Richard Amato for Precise Results
11. Baseball players enjoy successful long-term results after elbow surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the leading provider of ... clinical trials market. Similar to its approach in demonstrating positive outcomes in the healthcare ... by proving the value of eVisits to support virtual studies. , In ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... With certifications ... Invisalign® in Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new ... complications that traditional orthodontics can cause for some patients, which is why they offer ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Uniform Advantage ... collection featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA ... and cotton easy care stretch twill. , With trendy looks hitting the medical community, ...
(Date:6/20/2017)... Smithsburg, Maryland (PRWEB) , ... June 20, 2017 ... ... communication to the patient’s bedside, would like to officially welcome Anthony Stanowski, DHA, ... side-by-side with Dr. Stanowski whose insight and expertise in healthcare will provide invaluable ...
(Date:6/19/2017)... ... 2017 , ... The joyful summer wedding season is upon us, but it’s ... winter and wet spring have created ideal conditions for mosquitoes and ticks poised to ... pesky mosquitoes when a bride and groom are saying their "I do's,” observes Manuel ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... LAWRENCE, Mass. , June 2, 2017  NxStage ... advancing renal care, today announced new findings demonstrating positive ... NxStage ® System One™. The data will be ... 2017, in Madrid, Spain . ... Knowledge to Improve Home Dialysis Network in ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
Breaking Medicine Technology: